Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Data From Investigational Therapy Tezepelumab Phase 3 NAVIGATOR Trial in Patients With Severe Asthma Presented at the American Academy of Asthma Allergy & Immunology Annual Meeting
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 26, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive full results from the pivotal NAVIGATOR Phase 3 trial, which showed the potential of tezepelumab to be a first-in-class medicine in severe asthma. When added to standard of care (SoC), tezepelumab demonstrated a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma, compared to placebo.

Related Keywords

United States ,Puerto Rico ,Canada ,America ,American ,Trish Rowland ,Megan Fox ,Exchange Commission ,Clinical Trial Program ,Amgen ,Drug Administration Breakthrough Therapy Designation ,Astrazeneca ,Drug Administration ,Beigene Ltd ,American Academy ,Asthma Allergy ,Immunology Annual ,North America ,Amgen Board ,Thousand Oaks ,Uncontrolled Asthma ,ஒன்றுபட்டது மாநிலங்களில் ,ப்வெர்டோ ரிக்கோ ,கனடா ,அமெரிக்கா ,அமெரிக்கன் ,ட்ரிஷ் ரோலண்ட் ,மேகன் நரி ,பரிமாற்றம் தரகு ,மருத்துவ சோதனை ப்ரோக்ர்யாம் ,மகேன் ,அமெரிக்கன் கலைக்கழகம் ,ஆஸ்துமா ஒவ்வாமை ,நோயெதிர்ப்பு ஆண்டு ,வடக்கு அமெரிக்கா ,மகேன் பலகை ,ஆயிரம் ஓக்ஸ் ,